Study objective: We assess whether an automated prescription drug monitoring program intervention in emergency department (ED) settings is associated with reductions in opioid prescribing and quantities.
INTRODUCTION Background
Drug overdoses have overtaken motor vehicle crashes as the leading cause of accidental mortality, and this epidemic has been fueled by prescription opioid abuse. 1 Overdose deaths involving prescription opioids have quadrupled since 1999. From 1999 to 2015, more than 183,000 people have died in the United States from overdoses related to prescription opioids. 2 Emergency departments (EDs) are a frequent source for prescriptions for controlled substances 3 and represent particularly high-risk settings for physician shopping and drug diversion. [4] [5] [6] [7] Individuals predisposed toward the misuse or diversion of opioids may frequently seek prescriptions from EDs. 7, 8 Contributing factors include the episodic nature of emergency care, lack of a long-term patient-physician relationship, and, until recently, the absence of integrated data systems about previous controlled substance use.
Prescription drug monitoring programs represent one approach to addressing the prescription opioid epidemic. All but one state have adopted these electronic registries, which track dispensed controlled substances to unique patients. 9 Information in the prescription drug monitoring program may help providers identify high-risk patients, such as those with high dosages of prescribed opioids, multiple prescribers or dispensers, and overlapping prescriptions for opioids or other controlled substances.
Editor's Capsule Summary
What is already known on this topic Emergency physicians are under pressure to reduce opioid prescriptions.
What question this study addressed
Can automated access to prescription histories reduce opioid prescribing?
What this study adds to our knowledge These investigators compared the rate of emergency department opioid prescribing in a statewide Medicaid database before and after the implementation of automated prescription history alerts through the electronic medical record. They observed no change.
How this is relevant to clinical practice
As implemented in the state of Washington, automated access to prescription histories did not reduce opioid prescribing.
Importance
Information from prescription drug monitoring programs may result in more selective opioid prescribing. 10, 11 However, there are multiple logistic barriers to prescription drug monitoring program use by providers, including Web pages that are difficult to navigate, frequent requirements for password updates, and time needed to access clinically useful information. 12, 13 As a result, there has been limited provider use of prescription drug monitoring programs in the absence of mandates. [14] [15] [16] At least 10 states require that health care providers perform a prescription drug monitoring program query before prescribing opioids. 17 Recent evaluations suggest that the requirement for mandatory prescription drug monitoring program use is associated with reduced opioid prescribing to high-risk patients and less "shopping" behavior (multiple prescribers or pharmacies for controlled substances). 17, 18 Such mandates are controversial because they impose significant logistic burdens on prescribers without addressing usability barriers. In addition, the perception of a coercive requirement may erode provider support for the programs. 19 Finally, such mandates could encourage undertreatment of pain. Conversely, best available data suggest that voluntary prescription drug monitoring program use has limited effect on opioid prescribing behavior. 17 One potential solution is the automation of prescription drug monitoring program queries that "push" clinically relevant data to providers during a patient encounter. 12 This approach is noncoercive and eliminates many of the logistic barriers related to program use. Automated queries may be particularly appealing in ED settings, which are characterized by competing clinical demands and intense pressure to maximize patient throughput. Starting in November 2014, Washington State hospital EDs began implementing an automated prescription drug monitoring program query on a staggered basis ( Figure E1 , available online at http://www.annemergmed.com). This natural policy experiment mitigates potential confounding by indication (ie, providers selectively performing queries on patients at higher risk of opioid overdose or abuse) that may occur in the absence of automated queries. Understanding the effect of automated prescription drug monitoring program queries is particularly important for Medicaid beneficiaries, who have a 6-fold higher risk of fatal prescription opioid overdose compared with non-Medicaid populations. 20 
Goals of This Investigation
Using data from a large cohort of Medicaid beneficiaries, we assessed whether an automated prescription drug monitoring program intervention in the ED settings was associated with reductions in opioid prescribing and quantities. We were specifically interested in the effect of the intervention on patients with a history of high-risk controlled substance use.
MATERIALS AND METHODS
The Washington State prescription drug monitoring program became operational in October 2011. Beginning in November 2014, Washington State began implementation of an automated prescription drug monitoring program query into a preexisting, statewide Emergency Department Information Exchange. The exchange is an electronic database that tracks information for unique patients and generates alerts for ED providers, including reports about care guidelines, security events, and ED visit history. An Emergency Department Information Exchange query occurs nearly instantaneously at patient registration at all nonfederal EDs in Washington State. The new initiative integrates an automated prescription drug monitoring program query using patient last name, first name, and date of birth as mandatory fields. If any of 6 high-risk criteria established by the Washington State Department of Health are met when the prescription drug monitoring program is queried (Figure) , then a complete prescription drug monitoring program report is generated and incorporated into the Emergency Department Information Exchange report. ED providers can access this exchange-automated prescription drug monitoring program query information by clicking on an icon in their local electronic medical record systems. If the ED did not have an electronic medical record system, then a paper report was faxed to it. There is no requirement for providers to enter prescription drug monitoring program credentials to view query data. Providers may still perform a manual program query, although there is no requirement to do so.
Study Design
We performed a retrospective cohort study of ED visits by Washington State Medicaid beneficiaries from January 1, 2013, to September 30, 2015 . The end of the study time frame was selected as the last day before nationwide transition from the International Classification of Diseases, Ninth Revision (ICD-9) to the ICD-10 system to avoid confounding caused by coding artifacts (eg, for ED diagnoses and preexisting comorbidity codes).
Although all nonfederal hospitals in Washington State agreed to participate in the automated prescription drug monitoring program initiative, implementation dates varied by hospital and were dependent on the completion of sitespecific agreements with the state. We exploited the staggered implementation of automated prescription drug monitoring program queries while controlling for hospitalspecific effects and temporal trends on opioid prescribing. This approach allowed us to model variation from withinhospital changes over time and cross-hospital differences at a point in time. Of 86 eligible hospitals in Washington State, 65 completed implementation during the study period ( Figure E1 , available online at http://www. annemergmed.com).
The Washington State Health Care Authority provided enrollment information and medical claims for Medicaid beneficiaries, as well as prescription drug monitoring program dispensing data linked at the beneficiary level. All pharmacies are required to report dispensing of controlled substances to the prescription drug monitoring program, regardless of payment source (including non-Medicaid coinsurers or cash). The Washington State Department of Health also provided data on provider queries of the prescription drug monitoring program system (queries are captured for patients with any previous program record of a dispensed controlled substance). The institutional review boards of Washington State and of Oregon Health & Science University approved this study.
Selection of Participants
We included Washington State Medicaid beneficiaries who were enrolled between January 1, 2013, and September 30, 2015. We excluded members with a history of cancer because opioid treatment is accepted for cancer pain. 21 We excluded beneficiaries who were also enrolled for Medicare because Medicare data were unavailable to us. Children younger than 15 years were excluded. We excluded observations for members who were enrolled less than 3 months during the previous year to have sufficient data on preexisting comorbidities. Finally, we excluded patients who received hospice or nursing home care at any time during the study period because opioid analgesics are a widely accepted treatment for hospice patients, 21 and institutional providers are likely responsible for medication management in nursing facilities.
We analyzed visits made by eligible beneficiaries to nonfederal EDs in Washington State. ED visits were identified through an algorithm from the Healthcare Effectiveness Data and Information Set, which uses a combination of procedure, revenue, and place-of-service codes typically found on ED claims. 22 We excluded ED visits that resulted in hospital admission or observation services and visits for which a unique treating ED provider could not be identified from claims data. We also excluded ED visits that were associated with greater than 1,400 morphine milligram equivalents of prescribed opioids (equivalent to >280 tabs of 5-mg oxycodone) because these likely represented erroneous data. Finally, we excluded visits to hospitals (n¼3) with fewer than 100 eligible ED visits by Medicaid beneficiaries during the time frame.
Outcome Measures
The primary outcome was any outpatient dispensed schedule II or III opioid prescription prescribed within 1 day of the index ED visit. We matched prescribing date to within 1 day after the ED index visit to account for encounters that spanned midnight. We included buprenorphine, butorphanol, codeine, dihydrocodeine, fentanyl, hydrocodone, hydromorphone, levomethadyl, levorphanol, meperidine, methadone, morphine, opium, oxycodone, oxymorphone, pentazocine, tapentadol, and tramadol. 23 We included tablets, syrups and suspensions, films, and transdermal patches, and we excluded other formulations (eg, powders, sprays).
A secondary outcome was the total outpatient dispensed morphine milligram equivalents prescribed within 1 day of the index ED visit. We used the following conversion factors to calculate morphine milligram equivalents: buprenorphine patch 12.6, buprenorphine tablet 30; butorphanol 7, codeine 0.15, dihydrocodeine 0.25, fentanyl patch 7.2, hydrocodone 1, hydromorphone 4, levomethadyl 8, levorphanol 11, meperidine 0.1, methadone 3, morphine 1, opium 1, oxycodone 1.5, oxymorphone 3, pentazocine 0.37, tapentadol 0.4, and tramadol 0.1.
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The independent variable was the presence of the automated prescription drug monitoring program query. This was defined as a site-specific binary indicator that corresponded to the period either before (no exposure) or after (exposure present) implementation of the automated prescription drug monitoring program query system.
We included an expansive set of case-mix measures from claims data, evaluated during each calendar quarter. Demographics included age, sex, race and ethnicity, disability status, enrollment in Medicaid fee-for-service versus managed care programs, and enrollment in the Patient Protection and Affordable Care Act expansion cohort. A 1-year history of 17 physical health condition categories was evaluated with the Chronic Illness and Disability Payment System, which has been validated for use in Medicaid populations. 27 Specific mental health diagnoses were identified through medical claims using the previously described classification system by Ettner et al. 28 We created ED visit-level measures from claims data. We collected data on the hospital site of service, and identified whether the ED visit was associated with any pain-related discharge diagnosis (Table E1 , available online at http://www.annemergmed.com). [29] [30] [31] We used linked prescription drug monitoring program dispensing data to identify previous high-risk use of controlled substances, as defined by the Washington State Department of Health ( Figure) . All prescription drug monitoring program "look-backs" that define high-risk use were performed from the date of the index ED visit.
Primary Data Analysis
The unit of analysis was an ED visit. We used a multivariable logistic regression model to assess the association of automated prescription drug monitoring program queries with the primary outcome of any dispensed opioid. The independent variable of interest was a site-and time-specific binary indicator for implementation of the automated prescription drug monitoring program intervention. We adjusted for patient demographic and health characteristics, as well as presence of pain diagnoses. We included hospital fixed effects to control for any unobserved, time-invariant hospital confounders, and a linear time variable (quarters 1 to 11) to control for potential temporal trends. Because opioid prescribing practices over time may vary by hospital, we included an interaction term between hospital and time to account for site-specific temporal trends. We also used 3 indicator variables for calendar quarter to adjust for seasonality. Standard errors were clustered at the hospital level.
Because greater than 80% of ED visits did not result in opioid prescribing, we restricted the analysis of total morphine milligram equivalents to ED visits with an opioid prescription. To account for the highly skewed distribution of morphine milligram equivalents, we used a generalized linear model with log link and Wald variance family based on results of the modified Park's test. Covariates included in the model were the same as those described above for the primary outcome of any opioid prescribing, and standard errors were clustered at the hospital level.
We omitted 0.67% of observations from the analysis because of missing core demographics (age or sex). Observations with missing race and ethnicity were categorized as "unknown" and included in the analysis. Comorbidities, disability status, and eligibility under the Patient Protection and Affordable Care Act were coded as presence or absence of diagnosis codes and therefore had no missing values.
For both outcomes, we also assessed for potential effect modification by previous high-risk use of controlled substances. Automated prescription drug monitoring program queries might have a selective effect on patients with any of the 6 indicators of high-risk opioid use (Figure) . We included an interaction term in models between the binary indicators of high-risk status (any of the 6 indicators) and automated prescription drug monitoring program query. We further refined this analysis by restricting to the population of patients who are more likely to receive an opioid prescription: those with a pain diagnosis recorded for their visit.
Several factors may have resulted in an invalid prescription drug monitoring program query, such as data entry errors of name or date of birth, technical problems such as temporary unavailability of the prescription drug monitoring program, or initial inability to verify the patient's identity because of medical condition or intoxication. For this reason, we performed a sensitivity analysis focused on ED visits with evidence of a successful automated prescription drug monitoring program query, as determined by a query matching on a Medicaid beneficiary and performed on the day of a qualifying ED visit. ED visits occurring after implementation of automated queries were restricted to those in which a successful query was completed, but all ED visits by eligible patients in the preimplementation phase remained in the analysis. We restricted the sensitivity analyses to patients with any previous record of dispensed controlled substance because the Washington State prescription drug monitoring program only captures queries on such patients.
Finally, we assessed whether there were selective effects by specific high-risk factors because concern for opioid misuse may vary across the 6 indicators ( Figure) . We included interaction terms in models between the binary indicator of automated prescription drug monitoring program queries and each of the 6 individual high-risk factors. We performed this sensitivity analysis in the primary cohort of all ED visitors, as well as in the subgroup with a previous record of dispensed controlled substance as described above.
All results are presented as marginal effects (ie, absolute risk difference attributable to the intervention). Data management and analyses were completed with R (version 3.4.1; The R Foundation, Vienna, Austria) and Stata (version 14.2; StataCorp, College Station, TX).
RESULTS
We identified 1,187,237 eligible ED visits during the study period ( Figure E2 , available online at http://www. annemergmed.com). ED visit-level characteristics before and after site-specific implementation of the automated prescription drug monitoring program queries are presented in Table 1 . Compared with the ED visits occurring before policy implementation, those after automated prescription drug monitoring program queries were more often made by beneficiaries who were nonwhite, were men, and qualified for Medicaid benefits because of expansion through the Patient Protection and Affordable Care Act. There were otherwise no clinically important differences by age, history of physical or behavioral health conditions, previous markers of high-risk opioid use, or pain-related diagnoses. Table 2 displays the unadjusted percentage of ED visits that resulted in any opioid prescribing and the unadjusted average morphine milligram equivalent dispensed before automated prescription drug monitoring program query implementation (17.5%; morphine milligram equivalent median 75; interquartile range 60 to 112.5) and afterward (18.2%; morphine milligram equivalent median 75; interquartile range 60 to 112.5). Short-acting hydrocodone and oxycodone were the 2 most commonly prescribed prescription opioids both before and after the intervention (Table E2 , available online at http://www.annemergmed. com). Unadjusted proportion of opioid prescribing and morphine milligram equivalents dispensed as a function of time are illustrated in Figure E3 (available online at http:// www.annemergmed.com). Table 3 describes the adjusted associations between implementation of automated prescription drug monitoring program queries and outcomes. Program queries were not associated with significant changes in the proportion of visits with opioid prescribing (5.8 per 1,000 encounters; 95% CI -0.11 to 11.8) or in the amount of morphine milligram equivalents prescribed at these visits (2.66; 95% CI -0.15 to 5.48). There was no evidence of selective effect on visits for patients with previous high-risk opioid use, either for all ED visits (visits with any opioid 1.2 per 1,000 encounters, 95% CI -9.5 to 12.0; morphine milligram equivalents 1.22; 95% CI -3.39 to 5.82) or for visits with a pain-related diagnosis (visits with any opioid -2.5 per 1,000 encounters, 95% CI -15.9 to 10.8; morphine milligram equivalents 1.20, 95% CI -4.81 to 7.21). Among patients without previous high-risk opioid use who had a pain-related diagnosis, automated prescription drug monitoring program queries were associated with a small increase in the proportion of visits with opioid prescribing (13.3 per 1,000 encounters; 95% CI 3.4 to 23.1) relative to those for high-risk patients. We did not find evidence of differential quantity of prescribed morphine milligram equivalents by history of high-risk opioid use.
In the subcohort of beneficiaries with any previous dispensing of a controlled substance, the proportion of validated prescription drug monitoring program queries associated with an ED visit were 4% before the intervention and 71% afterward. Table 4 describes the results of the sensitivity analysis that compared ED visits of this subcohort with a confirmed prescription drug monitoring program query in the postintervention phase with all ED visits in the preintervention phase. There were small increases in both the proportion of visits with opioid prescribing (13.6 per 1,000 encounters; 95% CI 6.5 to 20.7) and prescribed morphine milligram equivalents (4.10; 95% CI 1.08 to 7.13) associated with the intervention. There was no evidence of decreased opioid prescribing or morphine milligram equivalents for patients with previous high-risk opioid use. We found that the intervention resulted in a relatively higher proportion of (Table E3 , available online at http:// www.annemergmed.com) or in the subcohort with a confirmed prescription drug monitoring program query in the postintervention phase (Table E4 , available online at http://www.annemergmed.com).
LIMITATIONS
First, we focused on Medicaid beneficiaries in a single state, and the generalizability of our findings requires external validation. Second, we were unable to match opioid prescriptions by treating ED providers because of high frequency of missing prescriber data. However, our approach of attributing opioid prescriptions results in almost identical estimates compared with a national sample of ED visits using chart review to ascertain opioid prescribing. 32 Third, although we exploited the staggered implementation of the automated prescription drug monitoring program to generate effect estimates, it is possible that our findings are confounded by unmeasured factors. Fourth, it is possible that providers did not check information in Emergency Department Information Exchange that was generated by the automated prescription drug monitoring program query. Fifth, the automated prescription drug monitoring program query would not have captured controlled substances dispensed in other states. Sixth, our sensitivity analysis of validated prescription drug monitoring program query was limited to patients with a previous prescription drug monitoring program record. However, we believe that ED providers are often unaware of previous controlled substance use, and we have no reason to believe that providers use prescription drug monitoring program data differentially for patients with and without previous controlled substance use. Seventh, our findings may be unique to the ED setting because of the challenges of acute pain management and episodic care. Automated prescription drug monitoring program queries may have different efficacy in outpatient settings.
DISCUSSION
In this large cohort of ED visits by Medicaid beneficiaries, an automated prescription drug monitoring program query intervention was not associated with reductions in opioid prescribing or quantities, even for patients with objective evidence of previous high-risk opioid use. These findings were robust to multiple sensitivity analyses, including restriction to pain-related visits, restriction to visits with a confirmed prescription drug monitoring program query in the postimplementation period, and assessment of 6 specific opioid high-risk indicators. We noted a small increase in opioid prescribing for patients without evidence of previous high-risk opioid use. These findings suggest limited efficacy of the policy to reduce opioid prescribing in ED settings. Paradoxically, the intervention may have increased the willingness of clinicians to prescribe opioids to patients without previous high-risk opioid use.
These findings are unexpected. The low proportion of prescription drug monitoring program usage in the preintervention period is consistent with other reports, [14] [15] [16] and the intervention markedly improved the proportion of ED visits with a validated prescription drug monitoring program query. Several state-level evaluations suggest that 18 may increase the efficacy of prescription drug monitoring programs. Several studies also suggest that providers alter prescribing behavior when given unsolicited prescription drug monitoring program data. 10, 39, 40 There are several potential explanations for our findings. Although the automated prescription drug monitoring program initiative was designed to minimize user burden by incorporating queries into the preexisting Emergency Department Information Exchange system, it is possible that providers did not access these data. It is possible that providers were unaware that a prescription drug monitoring program report had been generated, did not think that program data would change their management, or ignored reports because of "alert fatigue." 41 We noted that 71% of ED visits in the postimplementation period had verified queries. Mismatches may be attributable to invalid queries (eg, data entry errors, unable to obtain identifying information because of patient condition) and may have attenuated the effect of the automated query. However, we found no changes in our findings in sensitivity analyses that focused on patients with a validated prescription drug monitoring program query.
The automated prescription drug monitoring program initiative was implemented in the context of multiple Washington State policies aimed at inappropriate opioid prescribing in use during the past decade. 42 The state legislature enacted several mandates specifically targeting EDs in 2012, including the adoption of strict ED opioid prescribing guidelines and mandatory prescription drug monitoring program registration of all ED providers. 43 It is possible that these previous interventions altered ED opioid prescribing habits and attenuated the effect of the automated prescription drug monitoring program intervention. However, the observed proportion of opioid prescribing in our current study (ie, after the 2012 mandates) was identical to that reported from national data, 32 and we previously demonstrated a minimal effect of the hospital mandates on ED opioid prescribing. 44 The Washington State initiative generated a prescription drug monitoring program report for eligible encounters, but there were no accompanying recommendations or clinical decision support. Despite strict opioid prescribing guidelines that were in place during the study period, 45 ED providers may have been unaware of guidelines or uncertain about how to apply them to specific patient encounters in the context of prescription drug monitoring program information. For example, a previous survey of 515 ED providers in Florida suggested that 35% were unaware of opioid prescribing guidelines, and that 24% were aware but did not follow such guidelines. 16 Finally, acute pain treatment in the ED is fundamentally different from chronic pain management in outpatient settings. In some cases, it may be appropriate to treat acute conditions (eg, bone fracture) or exacerbation of chronic pain with opioid analgesics. The default approach for some ED providers may be to provide opioid pain control, and the value of the prescription drug monitoring program may be to justify this approach for patients without flags for previous high-risk use. Our study found evidence of small increases in opioid prescribing to patients without high-risk flags. Supportive findings have been reported from 2 smaller studies that assessed how prescription drug monitoring program data affected opioid prescribing by emergency physicians. In a study of 179 ED visits, prescription drug monitoring program data resulted in reduced opioid prescribing in 25% of encounters and increased opioid prescribing in 16% of encounters. 10 In another study of 544 ED visits, prescription drug monitoring program data decreased opioid prescribing in 3% of encounters and increased prescribing in 6%. 46 Our findings have important policy implications because the automated prescription drug monitoring program initiative requires monetary and staff resources. Program queries may need to be combined with provider education or decision support, although further studies are required to assess the efficacy of multimodal interventions. Automated queries may be less effective than prescription drug monitoring program use mandates in changing ED provider behavior.
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